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ABSTRACT 
 
 
Background 
Dengue virus (DENV) causes up to 390 million infections 
yearly, of which 96 million are clinically manifested. 
Approximately 500,000 people with severe dengue require 
hospitalization each year and there are at least 25,000 
deaths among children from Asian and Latin American 
countries. DENV is endemic in more than 100 countries. 
Chemical and biological controls have been implemented in 
targeting Aedes aegypti and Aedes albopictus mosquitoes, 
but these control practices failed to stem the dengue 
transmission. As a result, dengue vaccine has become a 
potential option recommended by WHO to be implemented 
in dengue endemic regions. Currently, several vaccine 
candidates are being evaluated in clinical studies. Amongst 
the vaccine candidates, live attenuated vaccines (LAV) are 
the furthest along the development pipeline. The most 
advanced vaccine, CYD-TDV (Dengvaxia) has been licensed 
in 19 countries. Several other live attenuated vaccines, as 
well as DNA, subunit, inactivated virus, viral-vectored and 
subunit-based vaccines, are under development and 
evaluation in preclinical or clinical studies. Each of the live-
attenuated vaccine candidates targets on molecular 
determinants of virulence in DENV, with the emphasis on 
attenuating the DENV and inducing a balanced tetravalent 
immune response against all the four dengue serotypes. 
 
Aims 
This review presents several different vaccine approaches 
and their construction strategies, providing an insight into 
the development of future dengue vaccines such as live 
attenuated vaccines, DNA vaccines, sub-unit protein 
vaccines and viral vectored vaccines.  
 
Methods  
Recent development status of dengue vaccine candidates 
was reviewed based on the published data and an online 
registry for clinical trials (ClinicalTrials.gov) which is run by 
the U.S. National Library of Medicine, National Institutes of 
Health.  
 
Results 
Increasing burden of dengue necessitates the development 
of a safe and efficacious tetravalent dengue vaccine. Various 
vaccine strategies are being developed for disease 
prevention, each has its own strengths and limitations. 
Dengvaxia is a licensed dengue vaccine in 19 countries but it 
has been suspended in the Philippines in December 2017 
due to its potential risks in children <9 years of age and 
seronegative vaccinees. TDV was able to elicit neutralizing 
antibodies as well as cross protective T cell responses 
against all four dengue serotypes and protected mice and 
nonhuman primates against challenge with wild type DENV. 
Seroconversion was achieved in both seronegative and 
seropositive adults and children <1.5 years of age with a 
single dose. TV003/TV005 was able to elicit multifunctional 
T cell response in addition to the humoral response. 
Seroconversion in 90 per cent of seronegative adults was 
observed with a single dose of TV005. However, eliciting a 
balanced immune response against all the four dengue 
serotypes remained the major impediment.  
 
Conclusion 
Dengvaxia has been launched in 11 countries but it has been 
withdrawn in the Philippines due to adverse effects in 
young children. Experimental vaccines such as TDV and 
TV003/TV005 are live attenuated vaccines which are 
currently in phase III clinical trials. Continued field trials will 
further our understanding of immune correlates of 
protection or risk. 
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What this review adds: 
1. What is known about this subject?  
Dengue infection is a serious public health problem. Unmet 
medical need requires an understanding of the current 
vaccine and development of future dengue vaccines. 
 
2. What new information is offered in this review? 
This review addresses the strengths and limitations of live 
attenuated vaccines and other experimental vaccine 
candidates such as DNA, viral-vectored and subunit vaccines 
in development. 
 
3. What are the implications for research, policy, or 
practice?  
Further research should unveil more effective dengue 
vaccines and this requires a better understanding of the 
immune correlates of infection. 
 
Introduction 
Dengue is a mosquito-borne disease of growing public 
health concern. An estimated 390 million infections occur 
annually, of which 96 million were manifested clinically.
1
 
With more than 40 per cent of the world’s population now 
residing in dengue endemic countries, development of an 
effective dengue vaccine becomes a high priority. Dengue 
virus (DENV), being the causative agent of dengue infection, 
is classified under the genus Flavivirus within the family 
Flaviviridae. DENV has a single-stranded positive sense RNA 
genome, which is approximately 10.7kb in size. The open 
reading frame consisting of three structural genes (C, prM 
and E) and seven non-structural genes (NS), is flanked by 5’ 
and 3’ untranslated regions. There are four antigenically 
distinct DENV serotypes (DENV1-4) which lead to 
asymptomatic dengue or symptomatic dengue, ranging 
from dengue fever to dengue haemorrhagic fever (DHF) and 
dengue shock syndrome (DSS). Primary infection with a 
particular dengue serotype confers life-long immunity for 
that serotype while the immunity to the other dengue 
serotypes is short-lived. It has been proposed that 
secondary infection with a different serotype potentially 
increases the risk of developing DHF and DSS due to 
antibody enhancement effect (ADE) and reduced T-cell 
immune responses.
2
 To control the dengue transmission, 
various combinations of chemical and biological controls 
had been implemented in targeting the dengue vectors, 
Aedes aegypti and Aedes albopictus mosquitoes and its 
breeding sites.
3
 However, these control practices were less 
effective to control the dengue transmission. Nevertheless, 
biological control such as Wolbachia-infected mosquitoes 
appears to be a promising strategy. Collectively, this 
approach and vaccination are recommended by WHO to 
effectively prevent the dengue disease in dengue endemic 
regions.
4
 Several vaccine candidates are being developed to 
prevent dengue disease (Table 1). Each of the vaccine 
strategies has its own strengths and limitations.  
 
Vaccine Strategies  
The development of dengue vaccine began as early as 1929. 
However, it has been hampered first by insufficient 
knowledge of the pathogenesis in dengue and later by the 
necessity to induce a balanced immune response against all 
the four dengue serotypes. In 1945, Sabin and Schlesinger 
reported the first successful dengue vaccine, whereby the 
‘Hawaiian’ strain of DENV was attenuated in mouse brain by 
serial passages.
5
 The attenuated strain was able to confer 
partial protection against DENV. However, its production 
was eventually terminated when DENV could be propagated 
in cell cultures, a theoretically safer production. Despite 
formidable challenges in developing dengue vaccines, 
remarkable progression towards clinical efficacy trials has 
been made in recent years. There have been several dengue 
vaccine candidates under development including live 
attenuated vaccines, inactivated vaccines, DNA vaccines, 
subunit vaccines and viral-vectored vaccines. Amongst these 
vaccine candidates, live attenuated vaccine (LAV) 
candidates are the furthest in the development, with the 
first ever vaccine showing some efficacy in phase III trials, 
licensed in December 2015.
6
 
 
1) Live Attenuated Vaccines 
Currently, there is no effective vaccine against all the four 
serotypes of DENV. The only licensed dengue vaccine is the 
chimeric YF17D-DENV tetravalent dengue vaccine, CYD-TVD, 
which was developed by Sanofi Pasteur. The CYD-TDV 
vaccine is licensed in 19 countries,
6
 and sold as Dengvaxia. 
Dengvaxia is a tetravalent chimeric vaccine comprising the 
yellow fever attenuated 17D virus strain encoding the pre-
membrane (prM) and envelope (E) structural genes of 
DENV1-4, respectively (Figure 1).
7
 
  
Dengvaxia is recommended for use in individuals from 9–45 
years old in dengue endemic regions. Efficacy of the vaccine 
has been evaluated in phase III clinical trials conducted in 
Asia (CYD14) and Latin America (CYD15), and a phase IIb 
trial (CYD23) in Thailand. However, based on the results of 
the phase III clinical studies, the overall efficacy of 
Dengvaxia was only 56.5 per cent, 60.8 per cent and 30.2 
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 per cent in Asia, Latin America and Thailand, respectively.8 
Dengvaxia confers higher protection against DENV-3 (73.6 
per cent) and DENV-4 (83.2 per cent), but lower protection 
against the two widely circulating dengue serotypes, DENV-
1 (58.4 per cent) and DENV-2 (47.1 per cent) in vaccinees 
above nine years of age (pooled efficacy of two clinical trials 
conducted in Asia and Latin America, respectively). 
Dengvaxia showed substantially low efficacy against all 
serotypes (44.6 per cent) amongst those aged below nine 
years (Table 2). The vaccine efficacy in individuals above 45 
years old has not been evaluated and remains unknown. 
The efficacy of Dengvaxia was found to be also dependent 
on the dengue serostatus of the vaccinees. The 
immunogenicity of Dengvaxia was lower (35.5 per cent) in 
individuals who were initially seronegative.
9
 
 
Dengvaxia has been shown to reduce dengue 
hospitalizations of vaccinees, with an efficacy of 65.6 per 
cent among individuals aged above nine years and 44.6 per 
cent among individuals aged below nine years (Table 2). 
However, an updated efficacy study revealed that children 
younger than nine years old (particularly among those aged 
two to five years old) were associated with an elevated risk 
of hospitalization when they were infected naturally three 
years after the vaccination.
10
 In fact, vaccinated children 
showed a 7.45-fold higher rate of hospitalizations when 
compared to non-vaccinated children.
11
 It is possible that 
Dengvaxia elicited only transient antibody-mediated 
immune responses in the younger children. The subsequent 
waning antibody levels would predispose the vaccinated 
children to subsequent infections. The imbalance in immune 
responses elicited by the individual components of 
Dengvaxia might also explain the increased risk of 
hospitalization observed in year three follow-up of 
vaccinees younger than nine years old and seronegative 
individuals. Therefore, the World Health Organization 
(WHO) recommended the limited use of Dengvaxia to 
individuals aged from 9–45 years old in dengue endemic 
regions with high transmission intensity where the 
seroprevalence is more than 70 per cent at nine years of 
age.
4
 However, following a declaration that Dengvaxia could 
pose health risks in people not previously infected, 
Dengvaxia was suspended in Philippines. Several children 
died from various complications allegedly attributed to 
Dengvaxia were reported.  
 
Thus, Dengvaxia has some benefits but some serious 
caveats for its use. The number of serious adverse events in 
vaccinated individuals (62 per cent) was much higher than 
that of the control group (38 per cent).
12
 Protection 
narrowly targeted only a certain age group (9-45 years old) 
of vaccinees and its low efficacy (35.5 per cent) for 
seronegative individuals, highlights the need for a more 
effective vaccine. Ultimately a dengue vaccine should be 
capable of conferring protection in seronegative individuals 
of all ages including the young children, irrespective of 
previous exposure to dengue or infecting serotype and thus 
pursuing alternative vaccine strategies is essential. 
 
Collaborating with the Centers for Disease Control and 
Prevention (CDC), TDV (DENVax) is a tetravalent 
recombinant live attenuated dengue vaccine, comprising a 
live attenuated DENV-2 virus strain and three chimeric 
viruses expressing the prM and E protein genes for DENV-1, 
3 and 4 in the DENV-2 genome (Figure 1).
13
 TDV vaccine 
strain has three key attenuation mutations in the viral 
genome: 5’UTR-57 C-to-T; NS1-53 Gly-to-Asp and NS3-250 
Glu-to-Val.  
 
TDV was well tolerated in children and adults aged 1.5-45 
years regardless of previous exposure to dengue infection. It 
was also found to be capable of inducing strong neutralizing 
antibodies and cross-reactive T-cell mediated responses to 
all four dengue serotypes. It showed favourable safety 
profile and mild adverse events in vaccine recipients, with 
varied seroconversion rates for the four different serotypes. 
However, it showed imbalanced seroconversion rates for 
the four different dengue serotypes. The seroconversion 
rate to DENV-4 (33 per cent) was much lower than the other 
three serotypes (>80 per cent) in a phase Ib randomised 
study.
14
 The hurdle in achieving a balanced immune 
response from a tetravalent vaccine might be due to the 
viral interference between the four chimeric virus strains or 
the differences in virus replication kinetics. Despite this, the 
vaccine continues to be developed through ongoing phase II 
and phase III clinical trials. The clinical trials have been 
initiated in Brazil (ClinicalTrials.gov Identifier: 
NCT02406729). The recruitment process was initiated in 
2016 and it is still ongoing. 
 
For a live attenuated vaccine containing known molecular 
determinants of attenuation, it is of utmost importance to 
evaluate the genetic stability of the attenuation 
determinants. When the TDV vaccine strain was serially 
passaged ten times in Vero cells, there was no evidence of 
reversion at the NS1-53 Asp and NS3-250 Val loci. However, 
reversion was observed at the 5’UTR-57-U locus in viral 
strains from 10 of the 18 passages tested. The level of 
reversion increased with the passage number, reaching >50 
per cent by passage 9, and >80 per cent of reversion levels 
by passage 10.
15
 These data indicated the instability of the 
mutation at 5’UTR-57-U, rendering its propensity to revert 
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at low passage number. Due to the limited number of 
mutations, the probability of reversion to the wild type 
genotype is of concern as RNA viruses have a mutability rate 
of 10
-4 
to 10
-6
 mutations per nucleotide copied in a 
replication cycle.
16
 Thus, there is a need to identify multiple 
attenuation determinant(s) such as in the E gene, non-
structural genes and 3’ UTR to generate a multiply-mutated 
vaccine strain with greater genetic stability. 
 
The third vaccine candidate, TV003/TV005 developed by the 
National Institute of Allergy and Infectious Diseases (USA), 
utilized structural gene chimerization and deletion of 30 
nucleotides in the 3’ untranslated region (3’ UTR) as the 
attenuation strategy. Chimeric DENV-2 component was 
created by substituting the prM and E genes of DENV-2 
serotype into the DENV-4∆30 backbone (Figure 1).
8
 
Amongst the different tetravalent formulations evaluated in 
clinical trials, both TV003 and TV005 showed promising 
results and were chosen for further evaluation and 
development. The TV005 has one log higher PFU in the 
dosage of rDEN2/4∆30 than that of TV003 vaccine 
candidate. The overall tetravalent neutralizing antibody 
response induced by a single dose of TV005 (90 per cent) 
was also higher than TV003 (74 per cent).
17
 The 
seroconversion to DENV-2 was observed to improve to 97 
per cent in those who received TV005. 
 
The protective efficacy of a single dose of TV003 was 
evaluated in ten healthy flavivirus-naïve individuals (NCT 
01931176). No vaccinees developed dengue fever. 
However, 80 per cent of the vaccinees developed diffuse 
macular-papular rash and 40 per cent developed 
neutropenia. Vaccinees were then challenged with the 
rDEN2∆30 vaccine six months after vaccination to evaluate 
the protective efficacy of TV003 (NCT02021968). TV003 was 
able to confer complete protection against viremia, rash 
and neutropenia. It will be further evaluated in dengue-
endemic areas with a larger population. A clinical trial 
evaluating the protective efficacy of TV005 has been 
completed in the United States (NCT02317900).  
 
The single dose vaccine candidate TV003 showed 
considerable promise, supporting its use in targeting 
populations unprimed by previous DENV infections. 
However, a primed population might respond even more 
robustly. A major caveat here is that the high tetravalent 
neutralizing antibody response may not equate with 
protection in the field, as shown by Dengvaxia in phase IIb 
trial.
18
 Concern was also raised in a combined TV003 and 
TV005 trial, where the tetravalent seroconversion rate in 
African American volunteers were significantly lower (57 per 
cent) than the non-African American volunteers (86 per 
cent). This implies that the protective efficacy of the vaccine 
candidate might vary in different races.
19
 
 
2) DNA Vaccines 
A DNA vaccine comprises a plasmid vector harbouring the 
gene(s) of interest encoding for antigen(s). The intracellular 
expression and processing associated with DNA vaccines 
enable the antigen presentation to the host immune system 
in the context of MHC class I system, facilitating the 
stimulation of specific cytotoxic effector T cells. A series of 
cellular interactions are then initiated to activate and 
proliferate T cells and B cells, stimulating both humoral and 
cellular immune responses. However, there is a risk of 
nucleic acid integration into the host genomic DNA, 
potentially inactivating tumour suppressor genes or activate 
oncogenes, and leading to neoplastic transformation of host 
cells.
20
 However, this risk appears to be a low probability 
event, occurring 3,000 times lower than rate of 
spontaneous mutation in mammalian cells. Another concern 
is that the host might produce anti-DNA antibodies when 
foreign DNA is detected, leading to autoimmune diseases. 
 
The DNA vaccine approach has the advantage of potentially 
MHC-I presentation, as in a natural infection, and 
subsequent T-cell responses. Since E protein contains the 
immunological epitopes for inducing neutralizing 
antibodies, E proteins become the major target molecules 
for developing dengue DNA vaccine. Another principal 
molecular candidate for developing DNA vaccine is the prM 
which acts as a chaperonin that is essential for the proper 
folding of the E protein during viral maturation.
21
 
 
In designing a monovalent DNA vaccine, the prM and E 
genes of DENV-1 serotype were cloned into a plasmid 
vector (pVR1012) under the control of the human 
cytomegalovirus promoter, generating the recombinant 
DNA vaccine, D1ME
100
. To enhance the immunogenicity of 
D1ME
100
, it was formulated with a lipid-based adjuvant, 
Vaxfectin and higher neutralizing antibody titres were 
demonstrated. The neutralizing antibody titres to the 
Vaxfectin-adjuvanted vaccine were at least 2–2.5 fold higher 
than the non-adjuvanted vaccine. However, the average 
neutralization titres against each of the dengue serotypes 
were observed to vary greatly, being the highest against 
DENV-2 and lowest against DENV-4.
22
 With the same 
adjuvant, Danko and colleagues conducted dose escalation 
Phase I clinical trial of a tetravalent dengue DNA vaccine 
(TVDV). No anti-DENV IgG antibody responses were 
detected in vaccinees administered with unadjuvanted 
TVDV. Minimal vaccine-induced neutralizing antibody 
 374 
 
[AMJ 2018;11(6):370-380] 
 
 
 responses were detected by screening enzyme-linked 
immunosorbent assay (ELISA) among the vaccinees 
administered with low dose (1mg) adjuvanted TVDV or high 
dose (2mg) adjuvanted TVDV. Despite the poor neutralizing 
antibody responses, high dose adjuvanted TVDV elicited 
anti-dengue IFNγ T-cell responses in 79 per cent of 
vaccinees.
23
 It was concluded that the rate of response 
appeared to be a dose-dependent trend.  
 
In a recent study, Zheng and colleagues (2017) inoculated 
mice with a new dengue DNA vaccine candidate (pVAX1-
D1ME) to evaluate its protective efficacy against DENV-1 and 
DENV-2. The monovalent DNA vaccine which expressed the 
prM and E proteins of DENV-1 induced both humoral and 
cellular responses after three doses (100μg each) of DNA 
vaccine delivered by intramuscular (IM) injection.
24
 The 
pVAX1-D1ME vaccine was able to confer protection to mice 
against lethal DENV-1 challenge. Similar result was observed 
for pVAX1-D2ME. The bivalent DNA vaccine candidate 
consisting of pVAX1-D1ME and pVAX1-D2ME was found to 
generate a balanced immunogenic response to both the 
dengue serotypes (DENV-1 and DENV-2) in BALB/c mice. 
Nevertheless, the end-point titres of neutralizing antibodies 
in the bivalent vaccine-immunized mice were lower when 
compared to those in the monovalent vaccine-immunized 
mice.
25
 Since the vaccine comprises two recombinant pVAX1 
plasmids, there might be viral interference between the 
DENV-1 and DENV-2 candidates in the bivalent formulation. 
This finding should be an important consideration in further 
research on the development of tetravalent dengue DNA 
vaccine. The safety and protective efficacies of the vaccine 
should be also further evaluated in in vivo studies involving 
non-human primates before proceeding to clinical trials.  
 
3) Viral-Vectored Vaccines 
Viral-vectored vaccines are based mostly on non-flavivirus 
backbones. In this approach, a virus serves as a vector to 
carry antigenic genes that are capable to elicit both humoral 
and cellular immune responses. Viral-vectored vaccines are 
capable of enhancing immunogenicity without an adjuvant 
and induce cytotoxic T lymphocyte response, leading to the 
elimination of virus-infected cells. Despite their efficacies, 
viral-vectored vaccines present some unavoidable 
problems. Previous exposure to the vector virus induces 
production of neutralization antibodies against the vector 
virus as shown in the use of cAdVax-DenTV which was later 
discontinued.
26
 Vaccination in such individuals might be 
ineffective as the pre-existing neutralization antibodies 
against the recombinant vector virus may eliminate them 
before they are able to induce an immune response.  
 
Venezuelan equine encephalitis (VEE) virus replicon 
particles (VRPs) have been demonstrated to induce both 
innate and adaptive immune responses in mice. White and 
colleagues constructed E85-VRP by cloning a C-terminally 
truncated soluble form of E, representing 85 per cent of the 
E protein into the VEE replicon plasmid, pVKE.
27
 It was 
demonstrated that E85-VRP was capable of inducing 
serotype-specific antibodies, predominantly targeting EDIII 
which has been identified as a major target of murine 
monoclonal antibodies. The E85-VRP elicited robust 
neutralizing antibody responses following two doses of a 
tetravalent vaccine administered to macaques 6 weeks 
apart induced 100 per cent seroconversion against all four 
dengue serotypes. The neutralizing antibodies protected all 
the rhesus macaques from all the four dengue serotypes.
27
 
To be selected as the priming vaccine in a prime-boost 
strategy with live-attenuated vaccine as the booster, it is 
important to conduct longer-term immunogenicity studies 
to address the duration of the neutralizing antibody 
responses induced by the vaccines after the final booster.
27
 
 
The second viral-vectored dengue vaccine candidate (MV-
DEN), developed by Themis Bioscience and Institut Pasteur, 
was constructed on the basis of expression of a single 
tetravalent DENV antigen construct from a live-attenuated 
measles virus vaccine vector. MV-DEN construct harboured 
the EDIII domains of all four DENV serotypes and the DENV-
1 M protein ectodomain (ectoM). The protective efficacy of 
the vaccine against all four DENV serotypes is currently 
being evaluated in macaques.
28
 
 
4) Subunit Protein Vaccines 
Recombinant subunit protein vaccines are composed of 
defined protein antigens derived from the pathogen of 
interest. Recombinant subunit vaccines have advantages 
and disadvantages over the other types of vaccines and 
have been successfully used for vaccination against HBV. 
The strategy for constructing dengue subunit protein 
vaccines were based on the successful HBV vaccines by 
expressing viral antigens in expression system. The principal 
disadvantage of subunit vaccine is the necessity of large 
amounts of purified antigens in creating the vaccine. Similar 
to purified inactivated vaccines, subunit protein vaccines 
require adjuvants to enhance their immunogenicity. 
Requirement of purified antigens and adjuvants increase 
the cost of the vaccine. The potential of contamination with 
pathogenic expression vectors that are used to produce the 
dengue antigens tend to lead to lower antigen yield.
29
 The 
primary advantages of a subunit vaccine include minimal 
reactogenicity and induction of balanced antibody 
responses, conferring complete protection against the four 
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dengue serotypes.
29
 This was demonstrated by Clements 
and colleagues
30
 who showed that their truncated 
recombinant DENV E protein subunits (80E), conferred 
protection against viral challenge in both the mouse and 
monkey challenge models. The E subunit truncated at 
amino acid 395 of the E protein was cloned into pMtt∆Xho 
vector. Expression of this gene construct resulted in the 
production of a truncated E protein subunit comprising 80 
per cent of the N-terminal of the E protein (DEN-80E).  
 
Low doses of the tetravalent antigens administered with 
ISCOMATRIX® adjuvants were highly immunogenic and 
capable of inducing protective immune responses in both 
murine and non-human primate models. However, when 
mice were administered with higher doses of the 
tetravalent antigen formulation, viremia breakthrough was 
observed in these animals. Although neutralizing antibodies 
demonstrated in vitro neutralization capacity, they did not 
have the sufficient neutralizing activity, avidity or specificity 
to control the viral infection in the animal models. This 
could be due to a shift in the antibody avidity or subclass, 
which have impacted the capability of the vaccine to 
neutralize the viruses.
30
 The complexities of neutralization 
highlight the multifactorial nature of neutralizing antibodies 
and the molecular mechanisms by which they confer 
protection against dengue viral infection.  
 
Govindarajan and colleagues
31
 evaluated the 
immunogenicity and efficacy of low, medium and high doses 
of the ISCOMATRIX
TM
 adjuvanted tetravalent DEN-80E 
subunits in non-human primates. Antibody responses were 
found to be balanced against all four dengue serotypes, 
except that the DEN4-80E responses remained low at all 
dosage levels. In terms of protective challenge, the 
vaccinated animals were protected upon challenge with 10
5
 
PFU of each of the four DENV serotypes for 12 months.
31
 
 
A small proof-of-concept phase I clinical trial 
(NCT00936429) was then initiated to evaluate the safety, 
tolerability and immunogenicity of a monovalent DEN1-80E 
adjuvanted with 1.25mg Alhydrogel
TM
 (HBV-001 D1).
32
 The 
neutralizing antibody titters in majority of the subjects 
waned over time. Alternative formulations or vaccination 
schedules are required to achieve high titre and durable 
neutralizing antibody responses that could confer long term 
protection against DENV.  
 
Conclusion 
Although Dengvaxia has been licensed to be marketed in 19 
countries, its efficacy against DENV-1 and DENV-2 which are 
predominant in Asia remained significantly low. Its limited 
efficacy based on the serostatus and age of the vaccinees, 
highlights the need to develop a universal dengue vaccine 
which confers a balanced immune response against all four 
dengue serotypes regardless of the serostatus and age of 
the individuals. TDV and TV003/TV005 are live attenuated 
vaccines which are currently in phase III clinical trials. An 
ideal live attenuated vaccine should show sufficient genetic 
stability. Larger pools of the human population from 
different ethnic groups in different geographical areas 
should be recruited in clinical trials to evaluate 
seroconversion across different ethnicities and of all age 
groups including seronegative subjects. The other vaccine 
strategies such as DNA vaccines, viral-vectored vaccines and 
subunit protein vaccines appeared to be potential vaccine 
candidates, but require more extensive evaluation in non-
human primates before initiating clinical trials. Improving 
downstream processes and antigen formulations may yield 
a cost-effective and affordable second generation dengue 
vaccines, which are less dependent on cold chain storage 
and distribution.  
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Table 1: Development status of current dengue vaccine candidates  
 
Vaccine 
approach 
Candidate name/Identifier Developer Phase Valency 
 
References 
 
Live 
attenuated 
vaccines 
Chimeric yellow fever virus dengue 
vaccine CYD-TDV 
Sanofi Pasteur 
Licensed Tetravalent 
33
 
Intertypic chimera DENVax CDC-Inviragen/Takeda Phase III Tetravalent 34 
TV003/TV005 US National Institutes of Health and Butantan  Phase III Tetravalent 8 
DNA 
vaccines 
DNA vaccine expressing prM and E protein Naval Medical Research Centre (NMRC), USA 
Phase I Tetravalent 
35 
Inactivated 
vaccines 
Purified inactivated vaccine (TDENV-PIV) GSK/US WRAIR/Fiocruz Phase I Tetravalent 36,37 
TLAV-TPIV 
Heterologous prime-boost with LAV and 
tetravalent purified inactivated vaccine 
Adjuvant: Alum 
WRAIR, USA 
Phase I Tetravalent 
38  
Viral-
vectored 
vaccines 
EDIII and DENV-1 ectoM expressed from 
live-attenuated measles virus vector 
Themis Bioscience / Institute Pasteur 
Preclinical (Mice) Tetravalent 
28 
E85 expressed from single-cycle VEE virus 
vector 
Global Vaccines Preclinical 
(Macaques) 
Tetravalent 
27 
Subunit 
protein 
vaccines  
Recombinant subunit vaccine-V180 Hawaii Biotech, Merck and Co. Phase I Tetravalent 32 
EDIII-p64k fusion proteins and EDIII-capsid 
fusion proteins  
Expression system: Escherichia coli 
Pedro Kourí Tropical Medicine Institute (IPK) / Center 
for Genetic Engineering and Biotechnology (CIGB)  
Preclinical 
(Monkeys) 
Monovalent 
39 
Bivalent 80E-STF2 fusion proteins  
Expression system: baculovirus/insect 
cells 
Vaxlnnate 
Preclinical 
(Mice and monkeys) 
Tetravalent 
40 
Consensus EDIII protein  
Expression system: Escherichia coli 
Taiwanese National Health Research Institute (NHRI) Preclinical 
(Monkeys) 
Tetravalent 
41 
Virus-like 
particles  
EDIII-HBsAg VLPs or ectoE-based VLPs  
Expression system: Pichia pastoris 
The International Centre for Genetic Engineering and 
Biotechnology (ICGEB) 
Preclinical 
(Macaques) 
Tetravalent 
42 
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Table 2: The vaccine efficacy against dengue serotypes in the CYD14 (Asia) and CYD15 (Latin America) clinical trials  
 
Serotype 
Efficacy of CYD14 (Asia) (10275 participants) Efficacy of CYD15  
(Latin America) (20869 
participants) 
Pooled efficacy of CYD14 + 
CYD15  
(9 years old and above) 
9 years old or above  Below 9 years old 
 
DENV-1 
 
65.7% 
(46.6-78.2) 
 
46.6% 
(25.7-61.5) 
54.8% 
(40.2-65.9) 
58.4% 
(47.7-66.9) 
 
DENV-2 
 
 
 
36.8% 
(-10.1-63.3) 
 
33.6% 
(1.3-55.0) 
50.2% 
(31.8-63.6) 
47.1% 
(31.3-59.2) 
 
DENV-3 
 
 
69.5% 
(31.9-87.0) 
 
62.1% 
(28.4-80.3) 
74.2% 
(63.9-81.7) 
73.6% 
(64.4-80.4) 
DENV-4 
 
87.9% 
(75.5-94.6) 
 
51.7% 
(17.6-71.8) 
80.9% 
(70.9-87.7) 
83.2% 
(76.2-88.2) 
 
All serotypes 
 
 
67.8% 
(57.7-75.6) 
 
 
44.6% 
(31.6-55.0) 
 
 
64.7% 
(58.7-69.8) 
 
 
65.6% 
(60.7-69.9) 
 
The efficacy of CYD14 (Asia) and CYD15 (Latin America) against dengue virus serotypes in individuals who aged 9 years and above and in individuals aged below 9 years. The Latin 
American trial involved only individuals above 9 years old (9-16 years old).
10
 The numbers in brackets indicate the 95% confidence interval.  
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Figure 1: The genetic structure and design of the three live-attenuated dengue vaccines furthest in development 
 
Sanofi Pasteur (Dengvaxia): 
 
 
 
CDC-Inviragen/Takeda (TDV):  
 
 
US National Institutes of Health (TV003/TV005): 
 
DENV-1 
DENV-2 
DENV-3 
DENV-4 
YFV 
The individual serotypes are designated 
by color (Green = DENV-1, Blue = DENV-2, 
Pink = DENV-3, White = DENV-4) and 
Yellow = Yellow Fever Virus (YFV)). Red 
Arrowheads represent the three key 
mutations that attenuated the virulence 
of the vaccine strains.  
 
